guest ::
| Home > Publications database > Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. > print |
| Home > Publications database > Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. > print |
| 001 | 294383 | ||
| 005 | 20250210112107.0 | ||
| 024 | 7 | _ | |a 10.1002/1878-0261.13747 |2 doi |
| 024 | 7 | _ | |a pmid:39478658 |2 pmid |
| 024 | 7 | _ | |a 1574-7891 |2 ISSN |
| 024 | 7 | _ | |a 1878-0261 |2 ISSN |
| 024 | 7 | _ | |a altmetric:169988840 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-02216 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Metzenmacher, Martin |b 0 |
| 245 | _ | _ | |a Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. |
| 260 | _ | _ | |a Hoboken, NJ |c 2025 |b John Wiley & Sons, Inc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1739182821_9306 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Feb;19(2):357-376 |
| 520 | _ | _ | |a Pancreatic ductal adenocarcinoma (PDAC) comprises two clinically relevant molecular subtypes that are currently determined using tissue biopsies, which are spatially biased and highly invasive. We used whole transcriptome sequencing of 10 plasma samples with tumor-informed subtypes, complemented by proteomic analysis for minimally invasive identification of PDAC subtype markers. Data were validated in independent large cohorts and correlated with treatment response and patient outcome. Differential transcript abundance analyses revealed 32 subtype-specific, protein-coding cell-free RNA (cfRNA) transcripts. The subtype specificity of these transcripts was validated in two independent tissue cohorts comprising 195 and 250 cases, respectively. Three disease-relevant cfRNA-defined subtype markers (DEGS1, KDELC1, and RPL23AP7) that consistently associated with basal-like tumors across all cohorts were identified. In both tumor and liquid biopsies, the overexpression of these markers correlated with poor survival. Moreover, elevated levels of the identified markers were linked to a poor response to systemic therapy and early relapse in resected patients. Our data indicate clinical applicability of cfRNA markers in determining tumor subtypes and monitoring disease recurrence. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a PDAC |2 Other |
| 650 | _ | 7 | |a cfRNA |2 Other |
| 650 | _ | 7 | |a liquid biopsy |2 Other |
| 650 | _ | 7 | |a subtype |2 Other |
| 650 | _ | 7 | |a therapy |2 Other |
| 700 | 1 | _ | |a Zaun, Gregor |0 0000-0002-3813-6961 |b 1 |
| 700 | 1 | _ | |a Trajkovic-Arsic, Marija |0 P:(DE-He78)f3d58748e1cfc4f7f191b6719ec5b39e |b 2 |u dkfz |
| 700 | 1 | _ | |a Cheung, Phyllis |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Reissig, Timm M |0 0000-0002-9955-5991 |b 4 |
| 700 | 1 | _ | |a Schürmann, Hendrik |0 P:(DE-He78)3e79424c5bab1c2011182d87880c1796 |b 5 |u dkfz |
| 700 | 1 | _ | |a von Neuhoff, Nils |b 6 |
| 700 | 1 | _ | |a O'Kane, Grainne |b 7 |
| 700 | 1 | _ | |a Ramotar, Stephanie |b 8 |
| 700 | 1 | _ | |a Dodd, Anna |b 9 |
| 700 | 1 | _ | |a Gallinger, Steven |b 10 |
| 700 | 1 | _ | |a Muckenhuber, Alexander |0 P:(DE-He78)8b642bc1c86616f9a16b7ff392b76a69 |b 11 |u dkfz |
| 700 | 1 | _ | |a Knox, Jennifer J |b 12 |
| 700 | 1 | _ | |a Kunzmann, Volker |b 13 |
| 700 | 1 | _ | |a Horn, Peter A |b 14 |
| 700 | 1 | _ | |a Hoheisel, Jörg |0 P:(DE-He78)c684a26e52cc44716354a4d15f530b4e |b 15 |u dkfz |
| 700 | 1 | _ | |a Siveke, Jens |0 P:(DE-He78)026e0a55b968f360a3c349689ce8a99c |b 16 |u dkfz |
| 700 | 1 | _ | |a Lueong, Smiths S |0 0000-0002-2776-6706 |b 17 |
| 773 | _ | _ | |a 10.1002/1878-0261.13747 |g p. 1878-0261.13747 |0 PERI:(DE-600)2322586-5 |n 2 |p 357-376 |t Molecular oncology |v 19 |y 2025 |x 1574-7891 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:294383 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)f3d58748e1cfc4f7f191b6719ec5b39e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 0000-0002-9955-5991 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)3e79424c5bab1c2011182d87880c1796 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)8b642bc1c86616f9a16b7ff392b76a69 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)c684a26e52cc44716354a4d15f530b4e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)026e0a55b968f360a3c349689ce8a99c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 0000-0002-2776-6706 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL ONCOL : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-01-06T16:01:33Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-01-06T16:01:33Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Open peer review |d 2023-01-06T16:01:33Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2023-01-06T16:01:33Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-25 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOL ONCOL : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-10-25 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-10-25 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)MU01-20160331 |k MU01 |l DKTK Koordinierungsstelle München |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)B070-20160331 |k B070 |l Funktionelle Genomanalyse |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)MU01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B070-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|